% | $
Quotes you view appear here for quick access.

Sucampo Pharmaceuticals, Inc. (SCMP) Message Board

  • biotech_venture_capitalist biotech_venture_capitalist Feb 28, 2013 7:19 AM Flag

    Good news coverage on SCMP:

    Another ophthalmology company, Sucampo Pharmaceuticals, Inc. (SCMP) - a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones - announced that the Japan Science and Technology Agency (JST) has adopted unoprostone isopropyl ophthalmic solution .15% in the Adaptable and Seamless Technology Transfer Program. As part of this program, R-Tech Ueno, Sucampo's development partner shall provide most of funding for Phase III clinical development of unoprostone isopropyl for retinitis pigmentosa (RP) - a genetic disease characterized by progressive, irreversible vision loss. There are no drugs or therapeutic procedures currently approved for the treatment of RP today. Currently, the FDA has granted orphan drug designation to unoprostone isopropyl for treatment of RP.

    This project is the only one out of 17 that was selected for this prestigious Technology Transfer Program. The agreement also provides Sucampo with the clinical data needed to file for an RP indication in the US and Europe, an important step in treating other ophthalmic diseases.

16.34-0.74(-4.33%)Jul 2 4:00 PMEDT